|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
ELV034596917 |
| 003 |
DE-627 |
| 005 |
20230624014245.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
180603s2015 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.earlhumdev.2015.08.003
|2 doi
|
| 028 |
5 |
2 |
|a GBVA2015012000027.pica
|
| 035 |
|
|
|a (DE-627)ELV034596917
|
| 035 |
|
|
|a (ELSEVIER)S0378-3782(15)00167-X
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
|
|a 610
|
| 082 |
0 |
4 |
|a 610
|q DE-600
|
| 082 |
0 |
4 |
|a 618.3/005
|q OCLC
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 082 |
0 |
4 |
|a 610
|q VZ
|
| 084 |
|
|
|a 44.45
|2 bkl
|
| 100 |
1 |
|
|a Gulack, Brian C.
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus
|
| 264 |
|
1 |
|c 2015
|
| 300 |
|
|
|a 5
|
| 336 |
|
|
|a nicht spezifiziert
|b zzz
|2 rdacontent
|
| 337 |
|
|
|a nicht spezifiziert
|b z
|2 rdamedia
|
| 338 |
|
|
|a nicht spezifiziert
|b zu
|2 rdacarrier
|
| 520 |
|
|
|a Patent ductus arteriosus (PDA) is common in extremely premature infants and associated with increased morbidity and mortality. Medical management of PDA uses either indomethacin or ibuprofen. Despite numerous studies, uncertainty exists as to which drug is safer or more effective; we sought to fill this knowledge gap.
|
| 700 |
1 |
|
|a Laughon, Matthew M.
|4 oth
|
| 700 |
1 |
|
|a Clark, Reese H.
|4 oth
|
| 700 |
1 |
|
|a Sankar, Meera N.
|4 oth
|
| 700 |
1 |
|
|a Hornik, Christoph P.
|4 oth
|
| 700 |
1 |
|
|a Brian Smith, P.
|4 oth
|
| 773 |
0 |
8 |
|i Enthalten in
|n Elsevier Science
|a Abdel-Aziz, Tarek Ezzat ELSEVIER
|t Study of serum leptin in well differentiated thyroid carcinoma: Correlation with patient and tumor characteristics
|d 2014
|g Amsterdam [u.a.]
|w (DE-627)ELV022803173
|
| 773 |
1 |
8 |
|g volume:91
|g year:2015
|g number:12
|g pages:725-729
|g extent:5
|
| 856 |
4 |
0 |
|u https://doi.org/10.1016/j.earlhumdev.2015.08.003
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_U
|
| 912 |
|
|
|a GBV_ELV
|
| 912 |
|
|
|a SYSFLAG_U
|
| 912 |
|
|
|a SSG-OLC-PHA
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_350
|
| 936 |
b |
k |
|a 44.45
|j Immunologie
|q VZ
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 91
|j 2015
|e 12
|h 725-729
|g 5
|
| 953 |
|
|
|2 045F
|a 610
|